The anti-ALS drug riluzole attenuates pericyte loss in the diabetic retinopathy of streptozotocin-treated mice

详细信息    查看全文

• 作者：Jeong A. Choi^a ; ¹ ; Yoo-Ri Chung^b ; ¹ ; ² ; Hyae-Ran Byun^a ; ³ ; Hwangseo Park^d ; Jae-Young Koh^a ; ^c ; ^{jkko@amc.seoul.kr} ; Young Hee Yoon^b ; ^{yhyoon@amc.seoul.kr}
• 关键词：AGE ; advanced glycation end products ; BRB ; blood-retinal barrier ; BSA ; bovine serum albumin ; DR ; diabetic retinopathy ; FBS ; fetal bovine serum ; FITC ; fluorescein isothiocyanate ; mLDL ; modified low-density lipoprotein ; MCP1 ; monocyte chemoattractant protein-1 ; NPDR ; nonproliferative diabetic retinopathy ; PBS ; phosphate-buffered saline ; PDGF ; platelet-derived growth factor ; PDGFR-β ; platelet-derived growth factor receptor-β ; PDR ; proliferative diabetic retinopathy ; PKC ; protein kinase C ; STZ ; stre
• 刊名：Toxicology and Applied Pharmacology
• 出版年：2017
• 出版时间：15 January 2017
• 年：2017
• 卷：315
• 期：Complete
• 页码：80-89
• 全文大小：2674 K
• 卷排序：315

文摘

The effects of riluzole were examined in streptozotocin-induced diabetic mice. The diameter of retinal vessels and the number of pericytes were severely reduced. The levels of MCP1 and PKC were increased, while riluzole reversed all changes. Riluzole attenuated the level of MCP1 in AGE- or mLDL-treated retinal pericytes. Riluzole attenuated both MCP1 induction and pericyte loss in diabetic retinopathy.